Senti Biosciences Reports Addl Positive Preliminary Data From Phase 1 Clinical Trial Of SENTI-202 For Treatment Of R/R Hematologic Malignancies Including AML

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified

5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort

4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care

Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months

Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; Register Here

Announces certain preliminary first quarter 2025 financial results and provides pipeline update

SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported additional positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for the treatment of relapsed/refractory (R/R) hematologic malignancies including acute myeloid leukemia ("AML"). As previously announced, the Company will host a conference call and webcast to discuss the presented data today, April 28, 2025, at 8:30 AM ET (details below).